A rifampicin test is a rapid laboratory assay—commonly a molecular PCR-based test—that detects Mycobacterium tuberculosis and mutations in the rpoB gene that confer resistance to rifampicin. Often performed with cartridge systems (e.g., GeneXpert), it provides results within hours to guide prompt treatment decisions and identify rifampicin-resistant or multidrug‑resistant TB.

Rifampicin is a bactericidal antibiotic that inhibits bacterial RNA synthesis. It’s a cornerstone of tuberculosis treatment (given in combination regimens), and is used in leprosy and certain serious staphylococcal or prosthetic-device infections as part of combination therapy. It’s also used short-term as prophylaxis for close contacts of meningococcal or Haemophilus influenzae type b cases.

No. GeneXpert is a cartridge-based molecular (PCR) diagnostic platform that detects pathogen DNA/RNA. It’s typically run on sputum, nasopharyngeal/throat swabs, urine or other clinical specimens (for TB, COVID-19, etc.), not routinely on blood. Some specialized assays or research uses may test blood, but the system is primarily intended for non-blood respiratory and tissue samples.

The confirmatory test for tuberculosis is mycobacterial culture of clinical specimens (e.g., sputum), which definitively demonstrates Mycobacterium tuberculosis and enables drug‑susceptibility testing. Rapid molecular assays (nucleic acid amplification tests such as Xpert MTB/RIF) provide quick, highly accurate confirmation and detect rifampicin resistance, but culture remains the diagnostic gold standard for definitive confirmation and susceptibility testing.

Rifampicin is a cornerstone of standard short‑course treatment for active tuberculosis, and regimens without it are generally longer and less straightforward. If rifampicin can’t be used (allergy or rifampicin‑resistant TB), cure is still possible but requires specialist‑managed, longer second‑line or newer drug regimens with closer monitoring. Latent TB can sometimes be treated without rifampicin (e.g., isoniazid).

TB spreads mainly when a person with active pulmonary TB coughs, sneezes, speaks or sings, releasing tiny airborne droplets others inhale. Prolonged, close indoor contact and poor ventilation raise risk. Latent TB is not contagious; only active respiratory TB typically transmits. TB is not spread by casual touch, sharing food, or surfaces; immunosuppression and crowded settings increase transmission risk.